Robin Hood Ventures
Robin Hood Ventures is an angel investor group based in Philadelphia, Pennsylvania, established in 1999. The organization focuses on early-stage, high-growth companies primarily in the Greater Philadelphia region. It provides capital, mentoring, and valuable connections to assist entrepreneurs in building successful businesses. Typically, Robin Hood Ventures invests between $250,000 and $500,000, often collaborating with other angel investors, institutions, and venture capitalists within its network. The firm has a diverse investment portfolio, spanning various sectors, including information technology services, software, life sciences, hard technology, consumer products, and financial technology. Since its inception, Robin Hood Ventures has invested in over 45 companies, emphasizing a hands-on approach to helping businesses achieve their potential.
BiologicsMD
Corporate Round in 2024
BiologicsMD, Inc. is a therapeutic development company based in Fayetteville, Arkansas, established in 2010. The company specializes in creating targeted therapies for hair loss and severe bone disorders. Its product pipeline includes BMD-1141, a hair cycle stimulator aimed at restoring normal hair growth and preventing hair loss by stimulating the hair cycle, and BMD-1231, a bone graft substitute designed for spinal fusion procedures. BiologicsMD focuses on developing recombinant fusion proteins that deliver potent stimulatory effects directly to specific receptors at the site of disease, allowing for sustained therapeutic exposure with either a single dose or infrequent dosing regimens. The company is also exploring various formulation and delivery methods for parenteral, local, and topical administration of its therapies.
BiologicsMD
Venture Round in 2022
BiologicsMD, Inc. is a therapeutic development company based in Fayetteville, Arkansas, established in 2010. The company specializes in creating targeted therapies for hair loss and severe bone disorders. Its product pipeline includes BMD-1141, a hair cycle stimulator aimed at restoring normal hair growth and preventing hair loss by stimulating the hair cycle, and BMD-1231, a bone graft substitute designed for spinal fusion procedures. BiologicsMD focuses on developing recombinant fusion proteins that deliver potent stimulatory effects directly to specific receptors at the site of disease, allowing for sustained therapeutic exposure with either a single dose or infrequent dosing regimens. The company is also exploring various formulation and delivery methods for parenteral, local, and topical administration of its therapies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.